IDEXX Laboratories, Inc. vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.16 (market cap $3.80B). The key difference: IDEXX Laboratories, Inc. is far larger — about 10.6× Vanguard Global ex-US Real Estate Index Fd ETF's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 277,049). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| IDXX | VNQI | |
|---|---|---|
Market Cap | $40.43B | $3.80B |
Volume | 692,164 | 277,049 |
Sector | Health | — |
52-Week High | $766.68 | $50.76 |
52-Week Low | $504.70 | $41.81 |
Typical Hold Time | 46 Days | 95 Days |
Enterprise Value | $41.32B | — |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
VNQI trades at $42.15, up 0.81% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF focuses on international real estate, offering diversification and a higher dividend yield than some peers, but key financial ratios are not disclosed in the provided data. Recent news highlights a significant drop in short interest and comparisons with competing real estate ETFs.
The outlook remains cautious due to weak technical momentum and global real estate market uncertainties. Opportunities include international diversification and income from dividends, but risks involve currency fluctuations, economic cycles abroad, and underperformance versus U.S. real estate. Investors should weigh the bearish technicals against long-term diversification benefits.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →